CeriBell, Inc.

CBLL Healthcare Medical Devices

CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.

25.04 2.60 −9.41%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−10.7×
Dividend yield
—
F-score
4/9
Altman Z
10.80
Beneish M
−2.42
Dividend safety
n/a

CeriBell, Inc. (CBLL) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, CeriBell, Inc. (CBLL) trades at a EV/Sales of 8.3×. Over the past ten years it has ranged from 0.8× (January 2025) to 9.2× (October 2026); the current reading is higher than 99% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 7.4× 261.74%
FY2024 2.1× (17.79%)
FY2023 2.5× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 6.2× 3.28%
Mar 2026 6.0× (19.45%)
Dec 2025 7.4× 124.53%
Sep 2025 3.3× (50.91%)
7 more quarters

Against its own ten years

Low 0.8× High 9.2×
Ten-year median 5.7×
Current reading's percentile 99

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CBLL